corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library item: 18628

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

 

Publication type: news

N.C. gets half a million in pharmaceutical marketing settlement
LocalTechWire 2010 Aug 23
http://localtechwire.com/business/local_tech_wire/news/blogpost/8177648/


Abstract:

North Carolina got a more than $500,000 share of fines paid by pharmaceutical manufacturer InterMune, Inc., as part of a national settlement that the company marketed its drug Actimmune for unapproved uses, Attorney General Roy Cooper said Monday.

Actimmune is approved for treatment of two rare diseases – chronic granulomatous disease (an inherited immune disorder) and severe, malignant osteopetrosis (a disorder that weakens the bones). However, between January 2001 and June 2003, the Food and Drug Administration found that the company promoted the drug as a treatment of idiopathic pulmonary fibrosis (a condition that harms lung tissue).

Under the settlement, InterMune will pay North Carolina, other states and the federal government a total of $36,944,043.63 million in damages, plus interest, to compensate Medicaid and various federal health care programs. North Carolina has recovered $569,740.05 to support state and federal Medicaid efforts in the state, Cooper said in a statement.

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.

Email a Friend